Immunoscore in Rectal Cancer

Status:	Completed
Conditions:	Breast Cancer, Lung Cancer, Colorectal Cancer, Skin Cancer, Ovarian Cancer, Cancer, Cancer, Bladder Cancer, Thyroid Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	8/31/2018
Start Date:	January 24, 2014
End Date:	July 17, 2018

A Study to Determine the Immunopheotype of Locally Advanced Rectal Adenocarcinoma and Its Correlation With the Efficacy of Neoadjuvant Chemoradiotherapy

This is an observational study of tumor samples and MRI imaging in patients with colorectal
cancers. A tumor sample, MRI scans, and treatment outcome data will be used for research
purposes to see if it is possible to predict patients' response to treatment.

The quality of the immune environment in colorectal cancer biopsy samples correlates with
disease-free survival and overall survival more so than current staging conventions. This
study will use a scoring system called 'immunoscore' to characterize the immune enviroment.
Researchers hypothesize that the immunoscore will correlate with outcomes of colorectal
patients treated with neoadjuvant chemoradiation.

Inclusion Criteria:

- Patients with a diagnosis of a rectal mass suspicious for or known to be an
adenocarcinoma of the rectum.

- Age > 18

- Ability to give informed consent and comply with the protocol. Patients with a history
of psychiatric illness must be judged able to understand fully the investigational
nature of the study and the risks associated with the therapy.

Exclusion Criteria:

- History of other malignancy in the past 2 years except carcinoma in situ of the cervix
or bladder, or non-melanomatous skin cancer

- Other medical or psychiatric conditions that in the opinion of the Principal
Investigator would preclude safe participation in protocol.

We found this trial at

sites

Providence Health & Services

Portland, Oregon 97213

from

Portland, OR